Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Paul ValensiDepartment of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, FranceAbstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Paul Valensi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9020f16cee36493a82daa650b99b669e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9020f16cee36493a82daa650b99b669e
record_format	dspace
spelling	oai:doaj.org-article:9020f16cee36493a82daa650b99b669e2021-12-02T00:50:12ZBiphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes1178-7007https://doaj.org/article/9020f16cee36493a82daa650b99b669e2009-06-01T00:00:00Zhttp://www.dovepress.com/biphasic-insulin-aspart-3070-biasp-30-in-the-treatment-of-type-1-and-t-a3229https://doaj.org/toc/1178-7007Paul ValensiDepartment of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, FranceAbstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix, biphasic insulin aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews the available literature on the pharmacology, efficacy and safety of BIAsp 30 in T1DM and T2DM from an online search of the PubMed database. Following injection, BIAsp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia. In T1DM patients, randomized controlled trials (RCTs) have shown that HbA1c reduction is similar, but postprandial glycemic control is better, with BIAsp 30 than with human insulin regimens. In T2DM patients, lowering of HbA1c and postprandial hyperglycemia with BIAsp 30 compare favorably with optimized oral antidiabetes drug treatment, insulin glargine, and, in obese patients, human premix. An increase in minor hypoglycemia with BIAsp 30 relative to basal insulin has been reported in T2DM patients, but major and nocturnal hypoglycemia rates are generally low. Findings from RCTs in T2DM patients are supported by large observational studies. In summary, BIAsp 30 once to three times daily represents a simple and effective tool for the modern management of diabetes.Keywords: biphasic insulin aspart, BIAsp 30, premix, type 1 diabetes, type 2 diabetes Paul ValensiDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 61-71 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Paul Valensi Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
description	Paul ValensiDepartment of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, FranceAbstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix, biphasic insulin aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews the available literature on the pharmacology, efficacy and safety of BIAsp 30 in T1DM and T2DM from an online search of the PubMed database. Following injection, BIAsp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia. In T1DM patients, randomized controlled trials (RCTs) have shown that HbA1c reduction is similar, but postprandial glycemic control is better, with BIAsp 30 than with human insulin regimens. In T2DM patients, lowering of HbA1c and postprandial hyperglycemia with BIAsp 30 compare favorably with optimized oral antidiabetes drug treatment, insulin glargine, and, in obese patients, human premix. An increase in minor hypoglycemia with BIAsp 30 relative to basal insulin has been reported in T2DM patients, but major and nocturnal hypoglycemia rates are generally low. Findings from RCTs in T2DM patients are supported by large observational studies. In summary, BIAsp 30 once to three times daily represents a simple and effective tool for the modern management of diabetes.Keywords: biphasic insulin aspart, BIAsp 30, premix, type 1 diabetes, type 2 diabetes
format	article
author	Paul Valensi
author_facet	Paul Valensi
author_sort	Paul Valensi
title	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
title_short	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
title_full	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
title_fullStr	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
title_full_unstemmed	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
title_sort	biphasic insulin aspart 30/70 (biasp 30) in the treatment of type 1 and type 2 diabetes
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/9020f16cee36493a82daa650b99b669e
work_keys_str_mv	AT paulvalensi biphasicinsulinaspart3070biasp30inthetreatmentoftype1andtype2diabetes
_version_	1718403451811004416

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Ejemplares similares